Study that only studies information for overcoming barriers and successfully implementing a free-of-cost Blinatumomab (immunotherapy medicine given in treatment of relapsed Acute Lymphoblastic Leukemia) facilitation program in a Low and Middle-Income countries like India
Not Applicable
- Conditions
- Health Condition 1: Z511- Encounter for antineoplastic chemotherapy and immunotherapy
- Registration Number
- CTRI/2023/08/056146
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. All stakeholders (Healthcare Professionals involved in administration of Blinatumomab)
2. All the patients and their caregivers receiving Blinatumomab therapy
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method